Alanine Aminotransferase (ALT) Comparison Test: Principles, Methods, and Clinical Applications

The Alanine Aminotransferase (ALT) comparison test is a critical laboratory procedure used to evaluate liver function by comparing ALT enzyme activity across different analytical methods or patient samples. This comprehensive guide covers the technical principles, sample requirements, testing protocols, and clinical applications of ALT comparative testing in modern clinical laboratories.

Technical Overview

Alanine Aminotransferase (ALT), formerly known as serum glutamic pyruvic transaminase (SGPT), is a key enzyme primarily found in hepatocytes. It catalyzes the reversible transfer of an amino group from L-alanine to alpha-ketoglutarate, producing pyruvate and L-glutamate. Because ALT is concentrated predominantly in the liver, its release into the bloodstream serves as a highly specific biomarker for hepatocellular injury.

An ALT comparison test refers to a systematic method comparison study in which the analytical performance of a new or alternative ALT assay is evaluated against an established reference method. These comparative experiments follow internationally recognized standards, such as CLSI EP09 guidelines, to verify accuracy, precision, and correlation between testing systems. The comparison typically involves analyzing paired patient samples on both systems and performing statistical analysis, including regression analysis, bias assessment, and Bland-Altman plotting.

• Reference interval for healthy adults: approximately 7 to 56 U/L (may vary by laboratory and instrument)
• Catalytic reaction: L-alanine + alpha-ketoglutarate converts to pyruvate + L-glutamate
• Detection wavelength: 340 nm (monitoring NADH oxidation in the UV kinetic method)
• Recommended reference method: IFCC 2002 method at 37 degrees Celsius with pyridoxal-5-phosphate activation

Testing Samples

Serum Samples

Serum is the preferred specimen type for ALT comparison testing. Venous blood should be collected in plain tubes without anticoagulant and allowed to clot completely before centrifugation. Hemolysis must be avoided because red blood cells contain significant ALT activity, which can falsely elevate results. Samples should be separated from the clot within two hours of collection and analyzed promptly.

Plasma Samples

Heparinized plasma is acceptable for ALT measurement on most automated chemistry analyzers. However, comparison studies must ensure that both evaluated methods use the same matrix type to avoid systematic bias caused by sample matrix differences. EDTA plasma may interfere with certain enzymatic reactions and is generally not recommended unless validated.

Sample Storage and Stability

• Stable at room temperature (20 to 25 degrees Celsius) for up to 24 hours
• Stable at refrigerated temperature (2 to 8 degrees Celsius) for up to 7 days
• Frozen samples (-20 degrees Celsius or below) remain stable for at least one month, but repeated freeze-thaw cycles must be avoided
• Minimum volume typically required: 500 microliters per test run

Testing Items

The ALT comparison experiment evaluates multiple analytical and performance parameters to establish equivalence or quantify differences between two measurement systems. Key testing items include:

• ALT catalytic activity concentration in U/L, measured across the clinically relevant range
• Correlation coefficient (r) between the comparative and reference methods, with acceptance typically set at r greater than or equal to 0.975
• Proportional bias and constant bias derived from regression analysis (ordinary least squares, Deming, or Passing-Bablok regression)
• Bland-Altman mean bias assessment against predefined allowable total error limits
• Within-run and between-run precision, expressed as coefficient of variation (CV), generally required to be below 3 to 5 percent
• Linearity verification spanning the analytical measurement range
• Lower limit of detection and lower limit of quantification
• Interference assessment for bilirubin, hemoglobin, lipemia, and common medications

Testing Methods

IFCC Reference Method (UV Kinetic Assay)

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference method is the gold standard for ALT measurement. The assay employs a coupled enzyme reaction: ALT converts L-alanine and alpha-ketoglutarate into pyruvate and L-glutamate, and lactate dehydrogenase (LDH) subsequently reduces pyruvate to lactate while oxidizing NADH to NAD. The rate of NADH disappearance, monitored spectrophotometrically at 340 nm, is directly proportional to ALT activity. Pyridoxal-5-phosphate is included in the reagent to fully activate the enzyme, ensuring accurate measurement in vitamin B6-deficient patients.

Comparison Study Protocol

A structured comparison experiment follows these essential steps:

• Select a minimum of 40 to 100 patient samples covering the full analytical range, including low, normal, and markedly elevated ALT concentrations
• Analyze each sample in duplicate on both the test method and the comparative method within the same time window
• Perform statistical regression analysis to calculate slope, intercept, correlation coefficient, and confidence intervals
• Generate Bland-Altman difference plots to visualize bias across concentration levels
• Compare observed bias with allowable performance specifications, such as biological variation-based limits
• Document all results in a validation report for regulatory and accreditation purposes

Quality Control

Two levels of quality control materials (normal and elevated) must be analyzed at the start of each run and at defined intervals. Control results must fall within established Levey-Jennings control limits before patient results are accepted. External quality assessment programs, such as proficiency testing schemes, provide ongoing verification of method accuracy relative to peer laboratories.

Applications

ALT comparison testing serves multiple critical purposes in laboratory medicine and clinical practice:

• Method verification and validation before implementing a new ALT reagent or instrument in the clinical laboratory
• Detection and monitoring of acute and chronic hepatitis, including viral hepatitis B and C
• Assessment of drug-induced liver injury (DILI) during pharmaceutical clinical trials and post-marketing surveillance
• Evaluation of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
• Screening of blood donors and pre-employment health examinations
• Monitoring liver health in patients receiving hepatotoxic medications, such as statins, tuberculosis drugs, and chemotherapy agents
• Harmonization of ALT results across laboratory networks to ensure consistent clinical interpretation

FAQ

What causes elevated ALT levels? Elevated ALT commonly indicates hepatocellular damage from conditions such as viral hepatitis, alcoholic liver disease, fatty liver disease, medication toxicity, or autoimmune hepatitis. Intense exercise and muscle injury may also cause mild elevations, though ALT is more liver-specific than AST.

How long does an ALT comparison experiment take? A complete method comparison study, including sample collection, duplicate testing, statistical analysis, and report generation, typically requires one to two weeks depending on sample availability and laboratory workflow.

What is considered acceptable agreement between two ALT methods? Acceptance criteria vary by laboratory policy, but generally a correlation coefficient above 0.975 with bias within allowable total error (often less than 16.7 percent based on biological variation data) demonstrates acceptable agreement.

Can fasting affect ALT comparison results? ALT is not dramatically affected by recent meals; however, comparison studies should use consistent collection conditions. Prolonged fasting or recent alcohol consumption can alter ALT activity, so standardized pre-analytical conditions are recommended.

Why is pyridoxal phosphate included in modern ALT reagents? Pyridoxal-5-phosphate is a coenzyme required for full ALT activity. Its inclusion ensures that samples from patients with vitamin B6 deficiency yield accurate results, aligning with IFCC recommendations for standardization.